Download App

Log in to access Online Inquiry
Company Overview More
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
CEO: Belanoff M.D., Joseph K.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

CORT Corcept Therapeutics
19.250+0.210+1.10%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
-7.36% 345.53M -49.28% 223.54M -29.58% 335.81M -15.73% 361.33M
-Cash and cash equivalents
18.1% 61.86M 1.87% 77.62M -29.58% 335.81M 209.84% 94.69M
-Short-term investments
-11.51% 283.67M -59.97% 145.92M -- -- -33.04% 266.64M
Receivables
22.42% 27.18M 5.45% 27.63M 5.45% 27.63M 20.73% 26.51M
-Accounts receivable
22.42% 27.18M 5.45% 27.63M 5.45% 27.63M 20.73% 26.51M
Inventory
2.65% 5.08M 1.59% 4.99M -15.16% 17.95M 3.67% 4.99M
Prepaid assets
9.66% 10.44M 54.02% 10.32M -- -- 14.4% 9.07M
Total current assets
-5.23% 388.22M -44.31% 266.46M -27.25% 381.39M -13.29% 401.9M
Non current assets
Net PPE
1.17% 3.54M -63.77% 1.52M -79.51% 514K -47.77% 2.25M
-Gross PPE
20.45% 6.76M -26.44% 4.44M -79.51% 514K -19.67% 4.88M
-Accumulated depreciation
-52.49% -3.21M -57.85% -2.93M -- -- -48.42% -2.64M
Investments and advances
-72.42% 22.57M 210.19% 112.28M -- -- 767.71% 133.85M
Non current deferred assets
1.86% 37.71M -13.13% 27.46M -13.13% 27.46M -12.35% 29.64M
Other non current assets
-21.22% 16.08M -24.48% 16.05M 7.69% 14.4M 3.98% 17.77M
Total non current assets
-44.04% 79.9M 68.72% 157.29M -10.77% 42.37M 159.8% 183.5M
Total assets
-15.26% 468.12M -25.88% 423.76M -25.88% 423.76M 9.6% 585.4M
Liabilities
Current liabilities
Payables
198.35% 20.79M -29.69% 7.42M -34.55% 6.91M 0.74% 6.56M
-accounts payable
33% 9.27M -34.55% 6.91M -34.55% 6.91M 0.74% 6.56M
-Total tax payable
-- 11.52M -- 513K -- -- -- --
Current accrued expenses
5.97% 29.22M 6.1% 26.26M -- -- -0.57% 26.68M
Current debt and capital lease obligation
9.53% 2.26M -74.34% 526K -- -- -48.57% 1.05M
-Current capital lease obligation
9.53% 2.26M -74.34% 526K -- -- -48.57% 1.05M
Current liabilities
40.99% 57.24M 0.1% 47.54M -34.55% 6.91M 3.97% 44.76M
Non current liabilities
Long term debt and capital lease obligation
-- 552K -- 0 -79.38% 526K -- 0
-Long term capital lease obligation
-- 552K -- 0 -79.38% 526K -- 0
Other non current liabilities
-- -- -- -- 14.82% 40.52M -- --
Total non current liabilities
208.34% 3.07M -54.51% 409K 8.46% 41.04M -70.44% 413K
Total liabilities
44.99% 60.31M -0.92% 47.95M -0.92% 47.95M 1.63% 45.17M
Shareholders'equity
Share capital
3.23% 128K 4.1% 127K -- -- 4.13% 126K
-common stock
3.23% 128K 4.1% 127K -- -- 4.13% 126K
-Preferred stock
-- 0 -- 0 -- -- -- 0
Retained earnings
105.59% 217.77M 136.45% 194.97M -- -- 188.54% 162.92M
Paid-in capital
13.49% 608.72M 14.57% 591.35M -- -- 15.08% 571.38M
Less: Treasury stock
216.6% 417.45M 441.48% 410.41M -- -- 203.75% 194.3M
Gains losses not affecting retained earnings
-642.57% -1.35M -154.7% -227K -- -- -80.07% 115K
Total stockholders'equity
-20.16% 407.81M -28.19% 375.81M -28.19% 375.81M 10.32% 540.23M
Total equity
-20.16% 407.81M -28.19% 375.81M -28.19% 375.81M 10.32% 540.23M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%